The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men

Sjödin, Anders; Gasteyger, Christoph; Nielsen, Anne-Louise Hother; Raben, Anne; Mikkelsen, Jens D.; Jensen, Jesper Bevensee; Meier, Dieter; Astrup, Arne

doi:10.1038/ijo.2010.87

Cited by 47 publications

(37 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increases in heart rate and blood pressure were also observed, which may limit further increases in dosing. In another phase II trial with overweight and moderately obese individuals, 2.0 mg of tesofensine was given daily for 7 days and 1.0 mg given daily for another 7 days [44]. The treatment group showed a 1.8 kg weight loss above placebo, higher satiety ratings and lower food intake.…”

Section: Obesity Drugs Under Developmentmentioning

confidence: 99%

New advances in models and strategies for developing anti-obesity drugs

Kim

Lin

Blomain

2013

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Introduction Obesity is a worldwide pandemic. Obesity-related health and economic costs are staggering. Existing strategies to combat obesity through lifestyle improvements and medical intervention have had limited success. Pharmacotherapy, in combination with lifestyle modification, may play a vital role in reversing the disease burden. However, past and current weight-loss medications have had serious safety risks, notably cardiovascular and psychiatric events. Areas covered We review the strategies for designing new anti-obesity drugs by describing those currently in development. We describe their target, mechanism of action, and developmental or regulatory status. We also discuss the problem of weight regain following weight loss, and its relevance to the long-term success of anti-obesity pharmacotherapy. Expert opinion For weight management drugs to achieve the safety and efficacy required to be impactful, current studies are uncovering and characterizing new targets, including new signaling circuits and hormones regulating appetite and metabolism, and re-evaluating the role of pharmacotherapy in weight management. To avoid the safety failures of many past weight-loss drugs, the models and strategies covered in this article incorporate recent advances in knowledge and technology. We discuss the emergence of cGMP signaling as a potentially transformative target in weight management. Modulating cGMP signaling may represent an ideal goal for an anti-obesity pharmacotherapy, reflecting some of the major themes described in the present review: targeting pathways that are newly realized as relevant for weight management; promoting safety by re-purposing drugs that are safe, proven, and approved for clinical use; and having a synergistic effect on multiple, reinforcing pathways.

show abstract

Section: Obesity Drugs Under Developmentmentioning

confidence: 99%

New advances in models and strategies for developing anti-obesity drugs

Kim

Lin

Blomain

2013

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

show abstract

“…Increases in heart rate and blood pressure were also observed, which may limit further increases in dosing. In another phase II trial with overweight and moderately obese individuals, 2.0 mg of tesofensine was given daily for 7 days and 1.0 mg given daily for another 7 days (Sjodin et al, 2010). The treatment group showed a 1.8 kg weight loss above placebo, higher satiety ratings and lower food intake.…”

Section: Obesity Therapies Under Developmentmentioning

confidence: 99%

Obesity pharmacotherapy: What is next?

Colon-Gonzalez

Kim

Lin

et al. 2013

Molecular Aspects of Medicine

View full text Add to dashboard Cite

The increase in obesity in the Unites States and around the world in the last decade is overwhelming. The number of overweight adults in the world surpassed 1 billion in 2008. Health hazards associated with obesity are serious and include heart disease, sleep apnea, diabetes, and cancer. Although lifestyle modifications are the most straightforward way to control weight, a large portion of the population may not be able to rely on this modality alone. Thus, the development of anti-obesity therapeutics represents a major unmet medical need. Historically, anti-obesity pharmacotherapies have been unsafe and minimally efficacious. A better understanding of the biology of appetite and metabolism provides an opportunity to develop drugs that may offer safer and more effective alternatives for weight management. This review discusses drugs that are currently on the market and in development as anti-obesity therapeutics based on their target and mechanism of action. It should serve as a roadmap to establish expectations for the near future for anti-obesity drug development.

show abstract

“…126 Tesofensine increases satiety and may increase energy expenditure. 127128 No pediatric studies have been reported.…”

Section: Current Pharmacotherapeutic Options For Obesity Treatmentmentioning

confidence: 99%

Pharmacotherapy for childhood obesity: present and future prospects

Sherafat-Kazemzadeh

Yanovski

2012

Int J Obes

View full text Add to dashboard Cite

Pediatric obesity is a serious medical condition associated with significant comorbidities during childhood and adulthood. Lifestyle modifications are essential for treating children with obesity, yet many have insufficient response to improve health with behavioral approaches alone. This review summarizes the relatively sparse data on pharmacotherapy for pediatric obesity and presents information on obesity medications in development. Most previously studied medications demonstrated, at best, modest effects on body weight and obesity-related conditions. It is to be hoped that the future will bring new drugs targeting specific obesity phenotypes that will allow clinicians to use etiology-specific, and therefore more effective, anti-obesity therapies.

show abstract

The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men

Cited by 47 publications

References 32 publications

New advances in models and strategies for developing anti-obesity drugs

New advances in models and strategies for developing anti-obesity drugs

Obesity pharmacotherapy: What is next?

Pharmacotherapy for childhood obesity: present and future prospects

Contact Info

Product

Resources

About